Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- Choueiri, Toni K
- Escudier, Bernard
- Powles, Thomas
- Mainwaring, Paul N
- Rini, Brian I
- Donskov, Frede
- Hammers, Hans
- Hutson, Thomas E
- Lee, Jae-Lyun
- Peltola, Katriina
- Roth, Bruce J
- Bjarnason, Georg A
- Géczi, Lajos
- Keam, Bhumsuk
- Maroto, Pablo
- Heng, Daniel Y C
- Schmidinger, Manuela
- Kantoff, Philip W
- Borgman-Hagey, Anne
- Hessel, Colin
- Scheffold, Christian
- Schwab, Gisela M
- Tannir, Nizar M
- Motzer, Robert J
- Schöffski, Patrick
DOIAbstract
Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs. This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.status: publishe
Add to ORKG